Press releasePRNewswire
Whitehawk Therapeutics
WHWK · NASDAQ
$3.19+$0.18 (+5.98%)TodayMarket closed ·
Prev close $3.01
Latest news
- Press releasePRNewswire
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
- Press releasePRNewswire
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
- Press releasePRNewswire
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
- Press releaseBusiness Wire
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development
- Press releasePRNewswire
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
- Press releasePRNewswire
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
- Press releasePRNewswire
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
- Press releasePRNewswire
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
- Press releasePRNewswire
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
- News
Whitehawk Therapeutics Q1 EPS $(0.32) Misses $(0.09) Estimate
- Press releasePRNewswire
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Press releasePRNewswire
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
- Press releasePRNewswire
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
- Press releasePRNewswire
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
- Press releasePRNewswire
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Press releasePRNewswire
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
- Press releasePRNewswire
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Press releasePRNewswire
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
- Press releasePRNewswire
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
- Press releasePRNewswire
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Press releasePRNewswire
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Press releasePRNewswire
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
- NewsMohd Haider
Whitehawk Therapeutics Dips Over 8% In After-Hours Trading Despite New Tempus AI Partnership
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsDylan Berman
Whitehawk Therapeutics Stock Is Trading Higher Thursday: What's Going On?
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.